Does BCBS Minnesota cover Ozempic?

Yes. BCBS Minnesota covers Ozempic for heart disease risk reduction with prior authorization. Other policy requirements and your plan's benefits also apply.

How long does a Ozempic approval last with BCBS Minnesota?

Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.

What does BCBS Minnesota require to renew Ozempic?

Heart Disease Risk Reduction — Applies to Employer plans. Continuation approved via same criteria as initial approval. Patient must still have T2DM diagnosis and A1C ≥ 6.5%. Continuation pathway also available if patient has been on a preferred agent within past 90 days.

How current is this information?

The oldest review date among the policies on this page is April 1, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

BCBS Minnesota coverage for Ozempic (Heart Disease

Applies to Employer plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction - Ozempic in T2DM with Established CVD or Multiple CV Risk Factors

All of:

Diagnosis of type 2 diabetes
A1C ≥ 6.5% confirmed by lab test
Requested agent will be used to reduce risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke)
Patient will NOT use requested agent in combination with a DPP-4 containing agent
Patient will NOT use requested agent in combination with another GLP-1 or GLP-1/GIP receptor agonist
No FDA labeled contraindications to the requested agent

Plus any one of:

Patient has established cardiovascular disease (e.g., MI, stroke, any revascularization procedure, TIA, unstable angina, amputation, symptomatic or asymptomatic coronary artery disease)
Patient has multiple cardiovascular risk factors (e.g., hypertension, dyslipidemia, family history of cardiovascular disease, smoking)

Documentation to bring

Documentation of type 2 diabetes diagnosis
Lab test results showing A1C ≥ 6.5%
Documentation of established cardiovascular disease (e.g., MI, stroke, revascularization, TIA, unstable angina, amputation, CAD) or documentation of multiple cardiovascular risk factors (HTN, dyslipidemia, family history of CVD, smoking)
Prescriber statement that the requested agent will be used to reduce risk of major adverse cardiovascular events
Confirmation that patient is not using a DPP-4 inhibitor concurrently
Confirmation that patient is not using another GLP-1 or GLP-1/GIP receptor agonist concurrently

Quantity limits

2 MG/3ML — 1 pen per 28 days
4 MG/3ML — 1 pen per 28 days
8 MG/3ML — 1 pen per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
Renewal: Continuation approved via same criteria as initial approval. Patient must still have T2DM diagnosis and A1C ≥ 6.5%. Continuation pathway also available if patient has been on a preferred agent within past 90 days.

Not covered when

Concurrent use with DPP-4 inhibitors
Concurrent use with another GLP-1 or GLP-1/GIP receptor agonist
Personal or family history of MTC or MEN 2
Type 1 diabetes

Policy note: CV risk reduction indication for Ozempic applies in patients with T2DM and established CVD or multiple CV risk factors. The policy does not exclude patients who have NOT failed metformin/insulin if the CV risk pathway is used — metformin/insulin trial is NOT required for this pathway. T2DM diagnosis and A1C ≥ 6.5% are still required. This is a bundled policy covering all GLP-1 indications under a single PA framework; the CV risk pathway is a qualifying exception to the metformin/insulin step therapy requirement.

source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Does BCBS Minnesota cover Ozempic for Heart Disease Risk Reduction?

Policy document